Agenus Inc (AGEN) Stock Price & Analysis
Agenus Inc (AGEN) fell 3.39% to USD 5.98 as of July 25, 2026 at 06:52 UTC, according to Nexqual real-time market data.
AGEN last closed at USD 6.19; the session ranged USD 5.81–6.23 on volume of 1,192,246 shares. Market capitalization is $249.02M, with a 52-week range of USD 2.71–8.7 (NCM). Source: Nexqual, July 25, 2026 at 06:52 UTC.
Key Statistics (as of July 25, 2026 at 06:52 UTC)
| Price | USD 5.98 |
|---|---|
| Change | ▼ 3.39% (down) |
| Previous Close | USD 6.19 |
| Open | USD 6.2 |
| Day Range | USD 5.81 – 6.23 |
| 52-Week Range | USD 2.71 – 8.7 |
| Volume | 1,192,246 shares |
| Market Cap | $249.02M |
| Exchange | NCM |
Technical Analysis (AGEN)
Nexqual's technical model rates AGEN "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 06:52 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 69.92 (neutral) |
| vs SMA50 | Above (USD 3.68) |
| MACD | 0.67 (positive) |
Analyst Ratings (AGEN)
Wall Street analysts rate AGEN "Strong Buy" based on 1 analysts, with a mean price target of USD 30 (range USD 30–30), per Nexqual as of July 25, 2026 at 06:52 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 30 |
| High Target | USD 30 |
| Low Target | USD 30 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (AGEN)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -0.4 |
| Revenue Estimate | $34.00M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.03 vs est 1.8 ▼ miss |
| 2025-12-31 | USD 0.68 vs est -1.3 ▲ beat |
| 2025-09-30 | USD -1.16 vs est 2.2 ▼ miss |
| 2025-06-30 | USD -1 vs est 1.35 ▼ miss |
Source: Nexqual, July 25, 2026 at 06:52 UTC.
Financials & Fundamentals (AGEN)
| Total Revenue | $123.87M |
|---|---|
| Revenue Growth (YoY) | +40.20% |
| Gross Margin | +97.39% |
| Operating Margin | +44.62% |
| Profit Margin | +52.16% |
| Current Ratio | 0.38 |
| Total Cash | $35.00M |
| Total Debt | $41.07M |
| Free Cash Flow | $-53.02M |
Source: Nexqual, July 25, 2026 at 06:52 UTC.
Financial Health Score (AGEN)
Nexqual rates Agenus Inc's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 06:52 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Strong — Operating margin 45% |
| Balance Sheet | Mixed — $35M cash vs $41M debt |
| Cash Flow | Weak — FCF negative: -$53M, burning cash |
| Efficiency | Mixed — No data |
Ownership (AGEN)
| Insider Ownership | +6.73% |
|---|---|
| Institutional Ownership | +36.77% |
| Shares Outstanding | 41.64M |
| Float | 37.19M |
| Short % of Float | +17.17% |
Source: Nexqual, July 25, 2026 at 06:52 UTC.
Leadership (AGEN)
Agenus Inc is led by Garo H. Armen (age 72), Founder, Interim CFO, Principal Financial Officer, CEO & Executive Chairman, per Nexqual as of July 25, 2026 at 06:52 UTC.
| Founder, Interim CFO, Principal Financial Officer, CEO & Executive Chairman | Garo H. Armen (age 72) |
|---|---|
| Director and President & CEO of MiNK Therapeutics | Jennifer S. Buell (age 50) |
| Vice President of Investor Relations & Corporate Development | Zack Armen |
Major Backers & Investors (AGEN)
Notable institutional backers of Agenus Inc include Siren, L.L.C., Marshall Wace LLP, Morgan Stanley, according to Nexqual as of July 25, 2026 at 06:52 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Siren, L.L.C. | 2.38% |
| Marshall Wace LLP | 1.54% |
| Morgan Stanley | 0.66% |
| Renaissance Technologies | 0.64% |
| Man Group PLC | 0.62% |
| SEI INSTITUTIONAL MANAGED TRUST-SIMT TAX-MANAGED SMALL/MID CAP FUND | 0.57% |
| Raymond James Financial, Inc. | 0.54% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 11.62% |
| BlackRock | 1.4% |
| Geode Capital | 0.78% |
Source: Nexqual, July 25, 2026 at 06:52 UTC.
From Agenus Inc's Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally.
- It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
- It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.
- In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BCRX | BioCryst Pharmaceuticals, Inc. | USD 9.34 | ▼ 1.79% |
| GERN | Geron Corporation | USD 1.42 | ▲ 0.71% |
| CRIS | Curis, Inc. | USD 4.89 | ▼ 1.01% |
| CLDX | Celldex Therapeutics, Inc. | USD 35.28 | ▲ 1.47% |
| ACAD | ACADIA Pharmaceuticals Inc. | USD 24.84 | ▼ 0.48% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:52 UTC. This page is informational and not investment advice.